Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
08
2021
accepted:
29
03
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
26
4
2022
Statut:
epublish
Résumé
For many drugs, mechanisms of action with regard to desired effects and/or unwanted side effects are only incompletely understood. To investigate possible pleiotropic effects and respective molecular mechanisms, we describe here a catalogue of commonly used drugs and their impact on the blood transcriptome. From a population-based cohort in Germany (LIFE-Adult), we collected genome-wide gene-expression data in whole blood using in Illumina HT12v4 micro-arrays (n = 3,378; 19,974 gene expression probes per individual). Expression profiles were correlated with the intake of active substances as assessed by participants' medication. This resulted in a catalogue of fourteen substances that were identified as associated with differential gene expression for a total of 534 genes. As an independent replication cohort, an observational study of patients with suspected or confirmed stable coronary artery disease (CAD) or myocardial infarction (LIFE-Heart, n = 3,008, 19,966 gene expression probes per individual) was employed. Notably, we were able to replicate differential gene expression for three active substances affecting 80 genes in peripheral blood mononuclear cells (carvedilol: 25; prednisolone: 17; timolol: 38). Additionally, using gene ontology enrichment analysis, we demonstrated for timolol a significant enrichment in 23 pathways, 19 of them including either GPER1 or PDE4B. In the case of carvedilol, we showed that, beside genes with well-established association with hypertension (GPER1, PDE4B and TNFAIP3), the drug also affects genes that are only indirectly linked to hypertension due to their effects on artery walls or their role in lipid biosynthesis. Our developed catalogue of blood gene expressions profiles affected by medication can be used to support both, drug repurposing and the identification of possible off-target effects.
Sections du résumé
BACKGROUND
For many drugs, mechanisms of action with regard to desired effects and/or unwanted side effects are only incompletely understood. To investigate possible pleiotropic effects and respective molecular mechanisms, we describe here a catalogue of commonly used drugs and their impact on the blood transcriptome.
METHODS AND RESULTS
From a population-based cohort in Germany (LIFE-Adult), we collected genome-wide gene-expression data in whole blood using in Illumina HT12v4 micro-arrays (n = 3,378; 19,974 gene expression probes per individual). Expression profiles were correlated with the intake of active substances as assessed by participants' medication. This resulted in a catalogue of fourteen substances that were identified as associated with differential gene expression for a total of 534 genes. As an independent replication cohort, an observational study of patients with suspected or confirmed stable coronary artery disease (CAD) or myocardial infarction (LIFE-Heart, n = 3,008, 19,966 gene expression probes per individual) was employed. Notably, we were able to replicate differential gene expression for three active substances affecting 80 genes in peripheral blood mononuclear cells (carvedilol: 25; prednisolone: 17; timolol: 38). Additionally, using gene ontology enrichment analysis, we demonstrated for timolol a significant enrichment in 23 pathways, 19 of them including either GPER1 or PDE4B. In the case of carvedilol, we showed that, beside genes with well-established association with hypertension (GPER1, PDE4B and TNFAIP3), the drug also affects genes that are only indirectly linked to hypertension due to their effects on artery walls or their role in lipid biosynthesis.
CONCLUSIONS
Our developed catalogue of blood gene expressions profiles affected by medication can be used to support both, drug repurposing and the identification of possible off-target effects.
Identifiants
pubmed: 35446883
doi: 10.1371/journal.pone.0266897
pii: PONE-D-21-26621
pmc: PMC9022833
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Carvedilol
0K47UL67F2
Timolol
817W3C6175
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266897Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1806-1808
pubmed: 28954807
Circulation. 2003 Nov 18;108(20):2498-504
pubmed: 14581400
Eur J Pharmacol. 2015 Jan 5;746:138-47
pubmed: 25446433
Int J Mol Sci. 2019 Apr 03;20(7):
pubmed: 30987118
Scand J Clin Lab Invest. 2007;67(2):237-45
pubmed: 17366003
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1896-901
pubmed: 12578971
BMJ. 1999 Jun 26;318(7200):1730-7
pubmed: 10381708
Ann Appl Stat. 2016 Jun;10(2):946-963
pubmed: 28367255
Sci Rep. 2017 Sep 21;7(1):12127
pubmed: 28935963
Circulation. 2013 Oct 29;128(18):2026-38
pubmed: 24014835
Int J Epidemiol. 2020 Oct 1;49(5):1439-1440h
pubmed: 32747942
Cell Physiol Biochem. 2017;42(2):495-505
pubmed: 28578349
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561
pubmed: 27534869
Brief Bioinform. 2016 Jan;17(1):2-12
pubmed: 25832646
Nat Commun. 2018 Mar 6;9(1):827
pubmed: 29511166
Nat Med. 2013 Jul;19(7):892-900
pubmed: 23749231
BMC Public Health. 2015 Jul 22;15:691
pubmed: 26197779
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334
pubmed: 33290552
Circ Res. 2015 Feb 27;116(5):789-96
pubmed: 25593281
Molecules. 2017 Jan 31;22(2):
pubmed: 28146135
Front Endocrinol (Lausanne). 2021 May 25;12:652246
pubmed: 34113316
Eur Heart J. 2020 Jan 7;41(2):253-254
pubmed: 31665282
J Transl Med. 2020 Jun 9;18(1):231
pubmed: 32517814
Eur J Epidemiol. 2014 May;29(5):325-36
pubmed: 24816436
Hypertension. 2020 Jun;75(6):1455-1463
pubmed: 32275191
J Lipid Atheroscler. 2020 Jan;9(1):8-22
pubmed: 32821719
Endocrinology. 2009 Feb;150(2):687-98
pubmed: 18845638
J Hypertens. 2006 Nov;24(11):2131-41
pubmed: 17053529
Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):1996-2013
pubmed: 31553664
J Cell Mol Med. 2018 Mar;22(3):1366-1382
pubmed: 29364567
Circ Res. 2019 Dec 6;125(12):1055-1066
pubmed: 31630621
Bioinformatics. 2015 Feb 15;31(4):608-9
pubmed: 25677125
Drug Discov Today. 2013 Apr;18(7-8):350-7
pubmed: 22897878
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
Bioinformatics. 2008 Jul 1;24(13):1547-8
pubmed: 18467348
Physiol Genomics. 2015 Sep;47(9):376-85
pubmed: 26152686
J Am Coll Cardiol. 2019 Aug 6;74(5):672-682
pubmed: 31370960
BMC Genomics. 2010 Jun 02;11:349
pubmed: 20525181
BMC Med Genomics. 2017 Oct 11;10(1):59
pubmed: 29020950
Nucleic Acids Res. 2010 Jan;38(3):e17
pubmed: 19923232